RxDoctor Payments Data

Gregory Spencer, MD

Internal Medicine · Oklahoma City, OKNPI 1821030826

Payments from drug & device makers

$1,990in general payments, 2019–2025

Across 144 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$243
  • Lilly USA, LLC$240
  • Boehringer Ingelheim$176
  • Novo Nordisk$175
  • Merck$163
  • GSK$145
  • plus $848 from 17 others

What the payments were for

  • Food & beverage$1,982100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,990 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$37,134
Medicare patients
171
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$53,326
TrulicityDulaglutide38$38,258
JardianceEmpagliflozin44$32,959
JanuviaSitagliptin Phosphate23$25,649
OzempicSemaglutide19$16,707
Spiriva RespimatTiotropium Bromide13$14,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,281
SymbicortBudesonide/Formoterol Fumarate11$2,604
Levothyroxine Sodium203$2,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,080
Omeprazole88$2,047
Atorvastatin Calcium202$1,837
Pravastatin Sodium119$1,599
Potassium Chloride65$1,553
Albuterol Sulfate HfaAlbuterol Sulfate47$1,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$53,32657 claims
Boehringer IngelheimJardiance, Spiriva Respimat$176$47,72257 claims
Lilly USA, LLCTrulicity$240$38,25838 claims
MerckJanuvia$163$25,64923 claims
Novo NordiskOzempic$175$16,70719 claims
GSKTrelegy Ellipta$145$14,28118 claims
AbbVieSynthroid$75$1,22611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →